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DoxorubicinTemperature-sensitive liposomes (TSLs) loaded with doxorubicin (Dox), and Magnetic Resonance Imaging
contrast agents (CAs), either manganese (Mn2+) or [Gd(HPDO3A)(H2O)], provide the advantage of drug
delivery under MR image guidance. Encapsulated MRI CAs have low longitudinal relaxivity (r1) due to
limited transmembrane water exchange. Upon triggered release at hyperthermic temperature, the r1 will
increase and hence, provides a means to monitor drug distribution in situ. Here, the effects of encapsulated
CAs on the phospholipid bilayer and the resulting change in r1 were investigated using MR titration
studies and 1H Nuclear Magnetic Relaxation Dispersion (NMRD) proﬁles. Our results show that Mn2+
interacted with the phospholipid bilayer of TSLs and consequently, reduced doxorubicin retention capabil-
ity at 37 °C within the interior of the liposomes over time. Despite that, Mn2+-phospholipid interaction re-
sulted in higher r1 increase, from 5.1 ± 1.3 mM−1 s−1 before heating to 32.2 ± 3mM−1 s−1 after heating at
60 MHz and 37 °C as compared to TSL(Gd,Dox) where the longitudinal relaxivities before and after heating
were 1.2 ± 0.3 mM−1 s−1 and 4.4 ± 0.3 mM−1 s−1, respectively. Upon heating, Dox was released from
TSL(Mn,Dox) and complexation of Mn2+ to Dox resulted in a similar Mn2+ release proﬁle. From 25 to
38 °C, r1 of [Gd(HPDO3A)(H2O)] gradually increased due to increase transmembrane water exchange,
while no Dox release was observed. From 38 °C, the release of [Gd(HPDO3A)(H2O)] and Dox was irrevers-
ible and the release proﬁles coincided. By understanding the non-covalent interactions between the MRI
CAs and phospholipid bilayer, the properties of the paramagnetic TSLs can be tailored for MR guided
drug delivery.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
In 1978, Yatvin et al. proposed the concept of temperature-
triggered release of a chemotherapeutic drug from the aqueous
lumen of temperature-sensitive liposomes (TSLs) composed of 1,2-
dipalmitoyl-sn-glycerol-3-phosphatidylcholine (DPPC) and 1,2-
distearoyl-sn-glycerol-3-phospatidylcholine (DSPC). The drug re-
mains encapsulated in the inner compartment of the TSLs at body
temperature, whereas the drug is released at temperatures close to
the melting phase transition temperature (Tm) of the lipid bilayer
[1]. For application in hyperthermia-mediated drug delivery, TSLs
are injected intravenously and release their payload in tumor tissuesdical Engineering, Eindhoven
indhoven, The Netherlands.that are externally heated to 41–42 °C. With this local drug delivery
approach, high concentration of drugs is reached at the tumor site,
thereby expanding the therapeutic window [2–4]. A milestone in
the development of TSLs was the incorporation of lyso-phospholipids
in the lipid bilayer, which speeds up the drug release kinetic and facili-
tates quantitative drug release [5,6]. The development of TSLs and their
applications are comprehensively reviewed by Landon et al. [7].
The concept of temperature-triggered drug release under magnetic
resonance (MR)-image guidance has been exploited by Viglianti et al.
[8–11] and de Smet et al. [2,12–14] using manganese (Mn2+) and
[Gd(HPDO3A)(H2O)] loaded liposomal doxorubicin (Dox), respectively.
This approach embarks on earlier research of using paramagnetic lipo-
somes loaded with Mn2+ [15,16] or Gd-chelates [2,17–25] as magnetic
resonance imaging (MRI) contrast agents (CAs). Encapsulation of para-
magnetic compounds in the lumen of a liposome leads to an apparent
reduction of the ionic longitudinal relaxivity (r1) as the water exchange
between the lumen and the surroundings is hampered by slow water
2808 S.Y. Yeo et al. / Biochimica et Biophysica Acta 1838 (2014) 2807–2816diffusion across the lipid bilayer. Subsequent release of the paramag-
netic CAs from the liposomal carriers then restores the r1, which has
been exploited to quantify [26,27] and image this process with MRI
[21]. However, the situation is more complicated for Mn2+ as it has
been demonstrated that Mn2+ interacts with the negatively charged
phospholipid head groups leading to an increase of its r1 as the rota-
tional correlation time increases [15]. As Mn2+ complexes Dox via
the anthraquinone (hydroxyketone) moieties and the amino-sugar
group, it can also be used as a liposomal loading agent [28–30]. For
image-guided drug delivery, the interaction of Mn2+ and Dox has
the advantage of ensuring concurrent release of both compounds
from the interior of the TSLs. Upon release from the interior of the li-
posomes, Mn2+ interacts with the negatively charged phospholipid
bilayer in the surrounding tissue which prolongs or even prohibits
the wash out from the tumor tissue to allow for better correlation
with drug distribution. Viglianti et al. demonstrated that the change
in the longitudinal relaxation rate (ΔR1), a consequence of co-release
of Mn2+ and Dox, can be exploited to monitor, localize and quantify
drug release in vivo [10]. Although preclinical results show promis-
ing application of TSLs containing Mn2+ and Dox for drug delivery
and dose painting [8,10], further development of such TSLs is hin-
dered potentially by the cellular toxicity of Mn2+ [31–33]. Alterna-
tively, [Gd(HPDO3A)(H2O)], a clinically approved MRI CA has been
co-encapsulated with Dox in the TSLs [2,13,18]. Similar to Mn2+, re-
lease of [Gd(HPDO3A)(H2O)] from the TSLs at elevated temperatures
enhances the MR signal in the surrounding tissue. However,
[Gd(HPDO3A)(H2O)] is an extravascular, extracellular CA that is
rapidly cleared from the circulation via renal excretion [34]. For ap-
plication in highly vascularized tumors, the rapid wash out of
[Gd(HPDO3A)(H2O)] may complicate the quantiﬁcation of drug con-
centration in situ as the pharmacokinetic and free volume of distri-
bution of [Gd(HPDO3A)(H2O)] and Dox are different.
Given the advantages and disadvantages of co-encapsulating Mn2+
and [Gd(HPDO3A)(H2O)] with a chemotherapeutic drug, the choice of      T > Tm
      TSL (Gd, Dox)
      TSL (Mn, Dox)
      T > Tm
Fig. 1. Schematic representation of temperature-induced delivery ofMRI CAs andDox at the Tm
the negatively charged phospholipid bilayer of the temperature-sensitive liposome.paramagnetic TSLs for in vivo use should bemadewisely and tailored
to a speciﬁc application. To date, these two temperature-sensitive
paramagnetic liposomal Dox formulations were evaluated using dif-
ferent phospholipid compositions and experimental conditions,
making a direct comparison difﬁcult. As one of the main beneﬁts of
paramagnetic TSLs is visualization of local drug delivery, in depth
understanding of the ΔR1 due to the type of CA encapsulated is cru-
cial and warranted to ensure accurate quantiﬁcation of local drug
concentration. In this paper, the interaction of the encapsulated
Mn2+ and [Gd(HPDO3A)(H2O)] with the phospholipid bilayer
(Fig. 1), and the change in r1 associated with this interaction, as
well as effects on stability of the formulation are investigated in
great detail through a series of MR titration studies and 1H nuclear
magnetic relaxation dispersion (NMRD) proﬁles.
2. Materials and methods
2.1. Materials
1,2-Dipalmitoyl-sn-glycerol-3-phosphatidylcholine (DPPC), 1-
palmitoyl-2-hydroxy-sn-glycero-3-phosphocholine (MPPC) and 1,2-
dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyeth-
ylene glycol)2000] (DPPE-PEG2000), were purchased from Avanti Polar
Lipids, Inc. [Gd(HPDO3A)(H2O)] (ProHance®) was obtained from Bracco
Diagnostics. Doxwas purchased fromAvaChemScientiﬁc andmanganese
sulfate (MnSO4) was purchased from Sigma-Aldrich.
2.2. Liposome preparation
All TSLs were prepared by using a lipid ﬁlm hydration technique,
where DPPC, MPPC and DPPE-PEG2000 were combined in a molar ratio
of 86:10:4. A total of 115 μmol phospholipid was dissolved in a chloro-
form:methanol solution of ratio 4:1 (v/v). The solvent was evaporated
using a rotary evaporator at 32 °C and a pressure of 20 mbar for one= Manganese (II) ions
 [Gd(HPDO3A)(H2O)]
Doxorubicin
= Phospholipid
= Lyso-phospholipid
=
=
= PEGylated phospholipid
of the lipid bilayer. Dashed lines show the non-covalent interaction of Mn2+ and Doxwith
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of 300 mM ammonium sulfate [(NH4)2SO4] (empty TSLs), 4.5 mL of
300 mMMnSO4 [TSL(Mn)] or 4.5 mL of 300 mM [Gd(HPDO3A)(H2O)]
and 120 mM [(NH4)2SO4] mixture [TSL(Gd)], all having a pH of 3.5.
Large multilamellar vesicles were downsized by successive extrusion
through 400 nm ﬁlters (two times), 200 nm ﬁlters (two times) and
100 nm ﬁlters (ﬁve times) at 60 °C. Following extrusion, the
extraliposomal buffers were replaced by performing dialysis against
300 mM sucrose/20 mM HEPES buffer at pH 7.5. Next, Dox (5 mg/mL
300 mM sucrose/20 mM HEPES) was added to all liposomes at a drug-
to-lipid weight ratio 0.05 to 1 and incubated at 33 °C for 90 min. The
unencapsulated Dox was removed by fractionating all liposomes
through PD-10 columns. TSLs containing Mn2+ and Dox [TSL(Mn,
Dox)] were royal purple, whereas TSLs containing [Gd(HPDO3A)(H2O)]
and Dox [TSL(Gd,Dox)] were orange. Three batches of liposomes were
prepared for each formulation.
2.3. Liposome characterizations
Phospholipid concentrations were determined based on the Rouser
method [35]. Intraliposomal Mn2+ and [Gd(HPDO3A)(H2O)] concen-
trations were determined by using Inductively Coupled Plasma-Mass
Spectrometry (ICP-MS, DRCII, Perkin Elmer). For determination of Dox
concentration, liposomes were destructed with Triton X-100 and the
amount of ﬂuorescence was measured at λex of 485 nm and λem of
590 nm (Perkin Elmer LS55).
Hydrodynamic radii (rh) of liposomes were determined using Dy-
namic Light Scattering (DLS) (ALV/CGS-3 Compact Goniometer System,
ALV-GmbH, Langen, Germany). The hydrodynamic rh was calculated
from the diffusion coefﬁcient rh = kT/(6 π η D) and corrected for the
viscosity of the sucrose containing buffer, η= 1.33 Pa∙s.
Differential Scanning Calorimetry (DSC) (Q2000 DSC, TA Instru-
ments, USA) was used to determine the Tm of the lipid bilayer. Tm is de-
scribed as the temperature at the onset of the DSC thermogram. All
samples were heated from 20 to 70 °C at 5 K/min.
The morphologies of TSLs were studied using cryogenic transmis-
sion electron microscopy (cryo-TEM). Samples were prepared using a
Vitrobot and studied using a FEI TECNAI F30ST at 300 kV. Subsequently,
images were recorded using a CCD camera (1 k × 1 k) [13].
2.4. MR titration studies/binding studies
Titration experiments were performed by addition of empty
TSLs to MnSO4 (0.3 mM) and [Gd(HPDO3A)(H2O)] (0.3 mM) solu-
tions to assess the effects of potential phospholipid and CA interac-
tions on r1. The longitudinal relaxation times (T1) of MnSO4 and
[Gd(HPDO3A)(H2O)] solutions prior to addition of TSLs (22 mM
phospholipid) were measured using Minispec 60 (Bruker, Ettlingen,
Germany) at 37 °C. Next, 10 μL of TSLs was added to 190 μL of each
sample and T1 was measured as well. The experiment involved addi-
tion of ten times 10 μL of empty TSLs (22 mM phospholipid) and T1
was recorded after each addition. From these measurements, r1
was calculated based on Eq. (1).
r1 ¼ 1
.
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‐
1
.
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where T1,0 is the T1 of sucrose buffer, T1 represents the measured T1
before or after heating and [CA] is the concentration of CAs in mM
and corrected for the dilution due to addition of TSLs. The r1 was
plotted against the phospholipid-to-CA concentration ratio.
The titration data were ﬁtted with a mathematical model, which
describes the non-covalent binding of CA to the phospholipid bi-
layer of TSLs (P) with N identical, independent binding sites [36,
37]. From this model, the binding stoichiometry between CA and
phospholipids (N), r1 of CA bound to phospholipids (r1, bound),and the association constant (Ka) were determined based on
Eq. (2).
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where r1 is determined experimentally (mM−1 s−1), r1,free is the
relaxivity of free CA (mM−1 s−1), r1,bound is the longitudinal
relaxivity of CA bound to phospholipids (mM−1 s−1), Ka is the as-
sociation constant (M−1), [P] is the phospholipid concentration
(M) and [CA] is the CA concentration (M). For ﬁtting, the longitudi-
nal relaxivity of Mn2+ was set to r1,free = 6.9 mM−1 s−1.2.5. Interaction of CAs with phospholipid bilayer after release
TSL(Mn) was prepared at a Mn2+ concentration of 0.25 mM. T1
was measured using Minispec 60 at 37 °C. Subsequently, the sample
was heated to 42 °C for 15 min to ensure complete release of encap-
sulated Mn2+, cooled to 37 °C and T1 was measured (Fig. 2). In a sec-
ond set of experiments, TSL(Mn) containing 0.25 mM Mn2+ was
heated to 42 °C for 15 min and cooled to 37 °C. The released Mn2+
was physically separated from TSLs using a 50 kDa Vivaspin ultraﬁl-
tration spin column. The pellets remaining at the ﬁlters were resus-
pended in 200 μL sucrose buffer. T1 of the supernatant (released
intraliposomal contents) and pellets (TSLs) were measured at 37 °C
(Fig. 2). Similar procedures were performed for TSL(Mn,Dox)
([Mn2+] = 0.29 mM), TSL(Gd) ([Gd(HPDO3A)(H2O)] = 1.52 mM)
and TSL(Gd,Dox) ([Gd(HPDO3A)(H2O)] = 1.59 mM). Two indepen-
dent measurements were performed for all samples, ﬁnal concentra-
tion of Mn2+ and Gd3+ in each sample was measured using ICP-MS
and r1 were calculated using Eq. (1).2.6. 1H nuclear magnetic relaxation dispersion (NMRD)
1H NMRD of 500 μL TSL(Mn,Dox) was measured at 35 °C to
prevent premature release of CAs from interior of the liposomes. Subse-
quently, the sample was heated to 42 °C for 20 min, cooled down to
35 °C in a water bath, and 1H NMRD was measured again at 35 °C. A
second sample was prepared by adding a mixture of Mn2+ and Dox
(Mn + Dox) to empty TSLs, and subjected to a similar 1H NMRD mea-
surement (TSL + Mn + Dox). The TSL + Mn + Dox measurements
were required to compare the effects of externally added Mn + Dox
to intraliposomally releasedMn+Doxon r1 at differentmagneticﬁelds.
As a control, a 1H NMRD of Mn+Doxwith a similarMn2+-to-Dox con-
centration ratio and Mn2+ were measured at 35 °C.
Similarly, 1H NMRD of [Gd(HPDO3A)(H2O)] in 500 μL of TSL(Gd,
Dox) was measured at 35 °C before and after heat treatment.
A separate sample was prepared by adding a mixture of
[Gd(HPDO3A)(H2O)] and Dox (Gd + Dox) to TSLs, and subjected to
the same 1H NMRD measurement (TSL + Gd + Dox). As a control, 1H
NMRD of Gd+Doxwith a similar [Gd(HPDO3A)(H2O)]-to-Dox concen-
tration ratio and [Gd(HPDO3A)(H2O)] was determined at 35 °C.
Sampleswere prepared in a 300mMsucrose/20mMHEPES buffer at
pH 7.5. Table 1 summarizes all measured samples and their respective
CA, Dox and phospholipid concentrations.
All 1H NMRD proﬁles were measured at magnetic ﬁeld strengths
ranging from 0.02 to 40 MHz using a Stelar SpinMaster FFC-2000
relaxometer, 60 MHz using Minispec 60 (Bruker, Ettlingen, Germany)
and 300 MHz using a 300 MHz high-resolution NMR spectrometer
(Bruker Avance, Ettlingen, Germany).
      15 min, 42oC            T1 at 37
oC
       Ultrafiltration
      Pre-heating, T1 at 37
oC       Post-heating
      TSLs (pellet), T1 at 37
oC
      CAs (supernatant), T1 at 37
oC
Fig. 2. Probing the release of encapsulatedMRI CAs from the aqueous lumen of a TSLwith T1. Post heating, the releasedMRI CAswere physically separated from TSLs using 50 kDaVivaspin
ultraﬁltration spin columns. Yellow squares representMRI CAs ([Gd(HPDO3A)(H2O)] orMn2+). This ﬁgure serves as a representation of the experimental steps taken and does not imply
the absence of CA in the liposomal fraction (pellet) as well as potential interaction with phospholipid bilayer.
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A ﬂuorescence spectrometer (Perkin Elmer LS55) was used to study
the release of Dox in a 300mM sucrose/20 mMHEPES buffer, pH 7.5, at
37 and 41 °C over time. Signal intensity was estimated with λex =
485 nm and λem = 590 nm. Subsequently, TSLs (2 μL) were added to
the buffer (2 mL). Fluorescent intensity was measured every minute
for one hour at 37 °C and every 15 s for 15min at 41 °C. The percentage
of Dox release was calculated according to Eq. (3),
% Dox release ¼ It–I0ð Þ= I100–I0ð Þ  100% ð3Þ
where It is theﬂuorescence intensity at a speciﬁc time, t, I0 is theﬂuores-
cence intensity at t = 0, and I100 is the ﬂuorescence intensity afterTable 1
A summary of all measured samples with their respective CA, Dox and phospholipid
concentrations.
Samples [CA] mM [Dox] µg/mL. [Phospholipid] mM
TSL(Mn,Dox) pre heating 0.6 278 7.5
TSL(Mn,Dox) post heating 0.6 278 7.5
TSL + Mn + Dox 0.6 278 7.5
Mn + Dox 0.6 278 –
Mn2+ 0.6 – –
TSL(Gd,Dox) pre heating 2.6 270 6.4
TSL(Gd,Dox) post heating 2.6 270 6.4
TSL + Mn + Dox 2.6 270 6.4
Gd + Dox 2.6 270 –
Gd(HPD03A)(H20) 2.6 – –addition of 5 μL 10% Trition X-100. Three different batches of liposomes
were measured for each liposomal formulation.
2.8. Release of intraliposomal contents during heating
The release of Dox was measured during heating from 25 to 50 °C
(heating rate= 0.5 K/min) using a ﬂuorescence spectrometer, whereas
release of CAs was studied bymeasuring the T1 during heating on a 300
MHz high-resolution NMR spectrometer (Bruker Avance, Ettlingen,
Germany) from 25 to 50 °C (heating rate = 0.5 K/min) and followed
by cooling down from 50 to 25 °C (cooling rate = 0.5 K/min). r1 was
calculated from the measured T1 values using Eq. (1).
3. Results
3.1. Liposome preparation and characterization
TSLs containing Dox and Mn2+ [TSL(Mn,Dox)] or [Gd(HPDO3A)
(H2O)] [TSL(Gd,Dox)] were prepared containing DPPC, MPPC and
DPPE-PEG2000 phospholipid in the lipid bilayer. DSC measurements
showed that the Tm was 39.9 °C for both liposomal formulations. As
evident from DLS, hydrodynamic radii of [TSL(Mn,Dox)] and
[TSL(Gd,Dox)] were 58 and 57 nm, respectively. The average
phospholipid, CA and Dox concentrations of TSLs are reported in
Table 2. The morphology of liposomes and encapsulated Dox was
studied by means of cryo-TEM. As shown in Fig. 3, before addition
of Dox, TSL(Gd) were spherical, whereas TSL(Mn) displayed a
faceted lipid bilayer morphology. The observed liposome morphol-
ogies were comparable to TSLs containing Mn2+ [29] and
[Gd(HPDO3A)(H2O)] [13] prepared by Chiu et al. and de Smet
Table 2
The average phospholipid, CA and Dox concentrations ± standard deviations of TSL(Mn,
Dox) and TSL(Gd,Dox) (n = 3).
Liposomal formulations [CA](mM) [Phospholipid](mM) [Dox](mM)
TSL(Mn,Dox) 0.54 ± 0.14 15.10 ± 1.37 0.62 ± 0.16
TSL(Gd,Dox) 4.53 ± 0.74 11.43 ± 1.10 0.95 ± 0.13
Fig. 4. Titration of TSLs to Mn2+ and [Gd(HPDO3A)(H2O)] to investigate the interaction
between phospholipid with MRI CAs on the r1 at 60 MHz and 37 °C. The black line repre-
sents the ﬁtted data.
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crystals were present in TSL(Mn,Dox) indicating Mn–Dox complex
formation [28], while self-assembled ﬁber-like Dox crystals were
evident in TSL(Gd,Dox) (Fig. 3) [13]. After heating, Dox crystals
were absent in either of the TSLs, indicating complete release of
Dox.
3.2. MR titration studies/binding studies
A titration study was performed to assess the interaction of MRI
CAs with the phospholipid bilayer of TSLs. If MRI CAs were to interact
with phospholipid bilayer, an increase in the rotational correlation
time (τr) is expected leading to an increase in r1 at 60 MHz. As shown
in Fig. 4, with increasing phospholipid-to-MRI CA concentration ratio,
an increase in r1 was indeed observed for Mn2+ in contrast to
[Gd(HPDO3A)(H2O)] where change of r1 was hardly observed. Taking
the r1 of Mn2+ as a ﬁxed parameter with r1,free = 6.9 mM−1 s−1,
the data were ﬁtted using the mathematical model describing the
non-covalent binding of Mn2+ to the phospholipids [36,37]. The ﬁt
values found for TSL + Mn are r1, bound = 48.5 mM−1 s−1, N = 0.04
and Ka = 9.3 × 104 M−1, respectively.
3.3. Interaction of CAs with phospholipid bilayer after release
To further investigate whether the non-covalent interaction of the
MRI CA with the phospholipid bilayer persists after release ofTSL (Mn)
TSL (Gd) TSL (Gd,Dox):
TSL (Mn,Dox):
Fig. 3. CryoTEM images of TSLs loaded with Dox aencapsulated Mn2+ or [Gd(HPDO3A)(H2O)] from TSLs, TSL(Mn),
TSL(Mn,Dox), TSL(Gd) and TSL(Gd,Dox) were heated to 42 °C and
cooled to 37 °C. Then, TSLs and the released intraliposomal contents
were physically separated using Vivaspin ultraﬁltration spin columns.
T1 data were measured at 37 °C and 60 MHz and r1 values were
calculated.
At 37 °C, r1 of TSL(Mn) was 5.3 ± 0.9 mM−1 s−1. After heating
for 15 min at 42 °C, r1 of TSL(Mn) at 37 °C increased to 34.7 ±
1.4 mM−1 s−1 (Fig. 5). When TSL pellets and the supernatant con-
taining the released intraliposomal contents were measured pre heating TSL (Gd,Dox): post heating
 pre heating TSL (Mn,Dox): post heating
nd MRI CAs. The scale bar represents 100 nm.
Fig. 5. An average change in r1 ± SD of TSLs before and after heat treatment (n= 2). “pre
heating” are samples without heat treatment; “post heating” are samples heated to 42 °C
for 15 min and measured at 37 °C; “pellet” are samples subjected to centrifugation and
containing TSLs; “supernatant” denotes samples subjected to centrifugation and contain-
ing released intraliposomal contents.
a
b
Fig. 6. (a) 1H NMRD proﬁles of TSL(Mn,Dox) pre and post heating, TSL + Mn + Dox,
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7.9 mM−1 s−1, while Mn2+ had a considerably lower r1 of 7.6 ±
1.0 mM−1 s−1 in the supernatant. Comparable results were obtain-
ed for TSL(Mn,Dox), with a r1 of 5.1 ± 1.3 mM−1 s−1 before heating
and 32.2 ± 3.0 mM−1 s−1 after heating. After separation, the r1 of
Mn2+ in TSL pellets and supernatant were 28.3 ± 2.2 mM−1 s−1
and 7.3 ± 0.7 mM−1 s−1.
For TSLs containing [Gd(HPDO3A)(H2O)], TSL(Gd) displayed r1 of
1.1 ± 0.1 mM−1 s−1 at 37 °C and 4.5 ± 0.2 mM−1 s−1 after heat treat-
ment for 15 min (Fig. 5). In contrast to Mn2+ containing TSLs, the r1
values of free [Gd(HPDO3A)(H2O)] were 5.9 ± 1.1 mM−1 s−1 in pellets
and 4.7± 0.5mM−1 s−1 in supernatant. For the liposomal formulations
encapsulatingDox, r1 values of TSL(Gd,Dox)were 1.2±0.03mM−1 s−1
before and 4.4 ± 0.3 mM−1 s−1 after heating. After separation, r1 of
[Gd(HPDO3A)(H2O)] in TSL pellets was 5.5 ± 0.5 mM−1 s−1 and
4.7 ± 0.4 mM−1 s−1 in supernatant.Mn + Dox and Mn2+ solutions; (b) 1H NMRD proﬁles of TSL(Gd,Dox) pre and post
heating, TSL + Gd + Dox, Gd + Dox and [Gd(HPDO3A)(H2O)].3.4. 1H nuclear magnetic relaxation dispersion (NMRD)
1H NMRD proﬁles for all samples listed in Table 1 were measured
at 35 °C to prevent premature release of CAs from interior of the li-
posomes. Before heating, the apparent r1 of the TSL(Mn,Dox) was
lower than that of Mn + Dox and Mn2+ solutions at magnetic
ﬁelds ranging from 0.02 to 300 MHz (Fig. 6a). This apparent
reduction of r1 with respect to free Mn2+ is due to the limited trans-
membrane water exchange across the phospholipid bilayer [38].
NMRD for Mn+Doxwas similar to freeMn2+ suggesting no observ-
able inﬂuence of Dox on r1 of Mn2+ at the measured concentration.
The Mn+ Dox proﬁle showed the classic behavior of aqueous Mn2+
ions where a ﬁrst dispersion was observed around 0.1 MHz due
to scalar interaction and a second dispersion was around 7 MHz
due to dipolar interaction. After heating of the TSL, the release of
Mn + Dox from the interior of the liposomes caused an increase in
the r1 (Fig. 6a). The increase in r1 is more prominent at magnetic
ﬁelds ranging from 3 to 60 MHz (Fig. 6a). It is important to note
that at magnetic ﬁelds higher than 0.3 MHz, the r1 of TSL(Mn,Dox)
after heating is higher than the Mn+Dox solution, suggesting bind-
ing of Mn2+ to the phospholipid bilayer. Interestingly, the 1H NMRD
proﬁles of TSL + Mn + Dox were higher as compared to TSL(Mn,
Dox) post heating with the exception of magnetic ﬁeld 0.3 MHzand below. This can be explained by an increased number of Mn2+
bound to the exterior phospholipids in the TSL + Mn + Dox when
Mn2+ was added to a TSL sample. On the other hand, after heating
and cooling of TSL(Mn,Dox), Mn2+ ions could be interacting with
the inner layer of the phospholipid bilayer, leading to re-
encapsulation of Mn2+ in the interior of the liposomes and thus,
resulting in a lower r1 as compared to TSL + Mn + Dox.
At magnetic ﬁeld strengths of 0.02 to 300MHz, TSL(Gd,Dox) has a r1
lower than Gd + Dox and [Gd(HPDO3A)(H2O)] solution before heat
treatment (Fig. 6b) due to limited transmembrane water exchange. In
line with earlier measurements [18], r1 values were higher and similar
to those of Gd + Dox solution following heat treatment of TSL(Gd,Dox).
External addition of Gd + Dox to empty TSLs also did not affect the r1
(Fig. 6b). All these data show that the contribution of non-covalent inter-
actions between the [Gd(HPDO3A)(H2O)] and the phospholipid bilayer is
limited. Furthermore, complete release of [Gd(HPDO3A)(H2O)] from the
lumen of the TSLs occurred. These observations were consistent with re-
sults on Fig. 5. The NMRD proﬁles of Gd-Dox and [Gd(HPDO3A)(H2O)]
were representative of low molecular weight Gd-chelate CAs.
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TSLs were designed to stably encapsulate intraliposomal contents at
37 °C and exhibit rapid release of intraliposomal contents at
hyperthermic conditions (N40 °C). The stability and release of Dox
were assessed using ﬂuorimetry at 37 and 41 °C. Following 2 min of
heating at 41 °C, TSL(Mn,Dox) and TSL(Gd,Dox) exhibited rapid release
of Dox up to 86 ± 3% and 98 ± 3%, respectively (Fig. 7). At 37 °C,
TSL(Mn,Dox) showed Dox released up to 61 ± 13% over a period of
one hour, whereas TSL(Gd,Dox) showed gradual release of Dox up to
12 ± 8% (Fig. 7a).3.6. Release of intraliposomal contents during heating
The release proﬁles of the two MRI CAs and Dox from TSLs were in-
vestigated where the release of Dox was followed using ﬂuorescence
spectroscopy and the release of MRI CAs was followed using a
300MHzNMR spectrometer. For the latter, the apparent r1was calculat-
ed from the measured R1 (1/T1) and the CA concentrations.
As the temperature was raised from 25 to 50 °C, Dox was gradually
released from TSL(Mn,Dox), with a sharp release starting at 38.3 °C
(Fig. 8a). Concurrently, the release proﬁle of Mn2+, plotted as r1, clearly
parallels the release proﬁle of Dox. Upon cooling, r1 remained high and
increased with decreasing temperatures. For temperatures below the
Tm of the TSLs, this increase is smaller compared to the temperaturea
b
Fig. 7. (a) Stability and release of Dox in HEPES buffered saline (HBS), pH 7.5, at 37 and
41 °C, respectively (n = 3). Dox release was plotted as average of percentages ± SD.
(b) Release kinetics of Dox within the ﬁrst 2 min at 37 and 41 °C.range above Tm. The trend of the observed Mn2+ release proﬁle
matches the Mn2+ release proﬁle from TSL (DPPC/MSPC/DSPE-
PEG2000) measured at 85 MHz [9].
TSL(Gd,Dox) remained stable at low temperature and exhibited a
rapid release of Dox at 37.3 °C. The the gradual increase in r1 from 25
to 38 °Cwas due to increased transmembranewater exchange, an effect
of temperature increase. From 38 °C, the irreversible release of
[Gd(HPDO3A)(H2O)] clearly coincided with the release of Dox. These
results verify that there were simultaneous releases of Dox and
[Gd(HPDO3A)(H2O)], which are consistent with results reported by de
Smet et al. using similar liposomal formulation [13] and Negussie et al.
using different TSL formulation (DPPC/MSPC/DSPE-PEG2000) [18].
4. Discussions
TSLs co-encapsulating MRI CAs and drug in their aqueous
lumen offer the prospect of visualization and quantiﬁcation of drug
release using MRI. Here, the effects of co-encapsulating Mn2+ or
[Gd(HPDO3A)(H2O)] with Dox and the interaction of Mn2+ and
[Gd(HPDO3A)(H2O)] with the phospholipid bilayer were investigated
and compared through cryo TEM images, stability and release studies,
MR titration studies and 1H NMRD proﬁles measurements.
As expected, at temperatures lower than Tm, the limited water ex-
change across the liposomal membrane results in low r1 of TSL(Mn,
Dox) and TSL(Gd,Dox) samples. After heating above the Tm, the r1 in-
creased for both types of liposomes, but a major difference is observed
between Mn2+- or [Gd(HPDO3A)(H2O)]-loaded liposomes. For Mn2+-
loaded liposomes, the NMRD proﬁles show a hump in the high ﬁeld re-
gion (10 to 100 MHz) typical of an interaction of Mn2+ ions with mac-
romolecular systems whereas, for [Gd(HPDO3A)(H2O)]-loaded
liposomes, identical r1 values were measured on the whole magnetic
ﬁeld range for [Gd(HPDO3A)(H2O)]-loaded TSLs, TSLs with external
[Gd(HPDO3A)(H2O)], [Gd(HPDO3A)(H2O)] in presence of Dox and
[Gd(HPDO3A)(H2O)]. These data conﬁrm the release of Mn2+ ions
and [Gd(HPDO3A)(H2O)] as well as a non-covalent interaction of
Mn2+ with phospholipids, which is clearly not observed for
[Gd(HPDO3A)(H2O)].
The MR titration and binding studies were performed with the aim
to assess and quantify the interaction of CAwith the negatively charged
phospholipid head groups. It is evident that Mn2+, titrated with empty
TSL or after hyperthermiamediated release from the interior of the lipo-
somes, interacts with the negatively charged phospholipid bilayer,
which is in line with results from Caride et al. [16]. This interaction
slowed down the molecular tumbling rate of Mn2+ and thus, resulted
in r1 values higher than those of free Mn2+ [10,39]. This observation is
supported by Koenig et al., who showed that when unilamellar
phosphatidylserine vesicles were added to Mn2+, the binding of
Mn2+ to the vesicles caused an increase in r1 up to approximately
42 mM−1 s−1 (20 MHz) [38]. The increase was most signiﬁcant at low
magnetic ﬁelds and gradually decreased at higher magnetic ﬁelds [38].
The derived Ka indicated non-covalent interactions between Mn2+
and the phospholipid bilayer. This explained the lower r1 of the pellet
fraction of TSL(Mn) and TSL(Mn,Dox) as compared to their respective
TSL post heating (Fig. 5). The lower r1 measured in the pellet fractions
of TSL(Mn) and TSL(Mn,Dox) might be due a mixture of TSL-bound
Mn2+ and free Mn2+ in the solution. For in vivo applications, the ob-
served interaction between Mn2+ and phospholipid bilayer is valuable
for several reasons. Cellular toxicity has always been a setback for clin-
ical applications of Mn2+ [31–33]. To date, onlyMn-DPDP (Teslascan®)
has been approved for clinical applications at a dose of 5 μmol/kg [40] or
10 μmol/kg [41]. For our formulation, a delivery of 0.5–1.3 mg/kg Dox
(=20–50 mg/m2) [42–44], which is a typical dose applied in clinical
settings for Doxil® (a clinically approved pegylated non temperature-
sensitive liposomal formulation of Dox), would result in a Mn2+ dose
of 0.8–2.0 μmol/kg. This range of Mn2+ doses is lower than Teslascan®,
making TSL(Mn,Dox) formulation an attractive candidate for clinical
ab
Fig. 8. (a) The release of Dox and Mn2+ from TSL(Mn,Dox) during heating from 25 to 50 °C (0.5 K/min), measured as a function of change in ﬂuorescence intensity and r1 at 300 MHz
magnetic ﬁeld, respectively. (b) The release of Dox and [Gd(HPDO3A)(H2O)] from TSL(Gd,Dox).
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atively charged phospholipids of the TSL is likely beneﬁcial for applica-
tions in MR image-guided Dox delivery in tumors with a high vascular
permeability. Interaction of Mn2+ with phospholipids in tumor envi-
ronments will result in slower downstreamwash out of Mn2+ as com-
pared to [Gd(HPDO3A)(H2O)] (an extracellular CA), hence enables
better correlation of MRI signals with local drug distributions in tumors.
Our study suggests that Mn2+ has an effect on the stability (drug re-
tention) of TSLs as compared to [Gd(HPDO3A)(H2O)] at 37 °C. Interac-
tion of Mn2+ with phospholipid bilayer resulted in higher leakage of
Dox from the interior of TSLs as compared to the leakage from a compa-
rable formulation, but containing [Gd(HPDO3A)(H2O)] instead of
Mn2+. Another possible explanation for the TSL(Mn,Dox) instability
might be the nature of the Dox precipitation within the liposomes
(Fig. 3). Abraham et al. have shown that liposomes encapsulating Dox
contained ﬁbrous-bundle aggregates of Dox precipitation [28]. Howev-
er, cryo-TEM images of liposomes containing both Mn2+ and Dox(Fig. 3) did not show similar Dox precipitation due to complexation of
Mn2+ with Dox. The absence of self-assembled ﬁber-like structure as
seen in TSL(Gd,Dox) [13], coupled with the diffusion of Mn–Dox com-
plexes across the phospholipid bilayer might be the contributing rea-
sons to the leakage of Dox at 37 °C. In addition, studies have shown
that the presence of transmembrane pH gradient plays a critical role
in the retention of Dox in liposomes [45]. However, the addition of
Mn2+ was reported to cause a loss of transmembrane pH gradient
[30], which may contribute to a higher leakage of Dox from TSL(Mn,
Dox) at body temperature. For future applications using TSL(Mn), phos-
pholipids with higher Tm could be used to improve the stability of
TSL(Mn), though any compromise on the rapid release kinetic at hyper-
thermic temperature needs to be avoided. Alternatively, Dox could be
loaded via complexation with Mn2+ in the presence of triethanolamine
(TEA) at neutral pH. In a comprehensive study, Kheirolomoom et al.
showed that Dox loading via a copper/TEA gradient improved the
drug retention capability in the interior of the liposomes at pH 7.4–8.5
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ingmethod needs to be further assessed for incorporation of Mn2+ and
Dox within the interior of TSLs.
Consistent with previous results, encapsulation of [Gd(HPDO3A)
(H2O)] did not affect the stability of TSL(Gd, Dox) [13,18]. Also,
results did not show interaction of [Gd(HPDO3A)(H2O)] with the
negatively charged phospholipid bilayer. One disadvantage of the ab-
sence of [Gd(HPDO3A)(H2O)] and phospholipid interaction is that
[Gd(HPDO3A)(H2O)] as an extracellular CA can be rapidly washed out
from the tumor tissues. However, [Gd(HPDO3A)(H2O)] is a clinically ap-
proved MRI CA [48] and Negussie et al. showed that 150 μmol/kg of
[Gd(HPDO3A)(H2O)] is required for MRI [18]. This concentration is
well below its LD50 (mice = 12,000 μmol/kg) [49] and comparable to
the diagnostic dose of 100–300 μmol/kg [50]. From this perspective,
clinical translation of TSL(Gd,Dox) is more achievable as compared to
TSL(Mn,Dox).
With the introduction of MRI guided High Intensity Focused Ultra-
sound (MR-HIFU) to induce hyperthermia non-invasively, paramagnet-
ic TSLs become amore attractive and desirable option to transport drugs
to diseased tissues. Preclinical studies thereafter also consistently show
that MR-HIFU induced hyperthermia was able to increase drug concen-
tration at tumor tissues compared to non-HIFU treated tumors [2,51].
The recent development and application of TSLs in combination with
MR-HIFU for drug delivery has been reviewed in detail [52–54]. Given
the demonstrated ability of paramagnetic TSLs for image guided drug
delivery, the inﬂuence of Mn2+ and [Gd(HPDO3A)(H2O)] on TSL stabil-
ity andMRI signal enhancement (ΔR1) should bewell understood to en-
sure accurate interpretation of drug dosage delivery in vivo.
5. Conclusions
The non-covalent interactions of encapsulated MRI CAs with
the phospholipid bilayer of the TSLs can be a double-edged sword.
Though the interaction of Mn2+ with the phospholipid head groups re-
duced the drug retention capability of the TSLs as compared to
[Gd(HPDO3A)(H2O)], the increase in r1 due to Mn–phospholipid inter-
action can be exploited to reduce Mn2+ concentration in vivo. In addi-
tion, the interaction of Mn2+ with the phospholipids of the targeted
tissue can lead to a prolonged retention of Mn2+ in situ, which makes
drug quantiﬁcation more independent of the exact perfusion of the
tumor. Equipped with thorough understanding of CA-phospholipid in-
teractions, TSLs can be designed to incorporate different phospholipids
in combination with Mn2+ or [Gd(HPDO3A)(H2O)] for MR guided
drug delivery.
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